Table S4.
Adverse events for GT3 patients
| Common adverse events | Patients receiving IFN-based therapy (n=10) N (%) | Theoretical patients receiving SOF/DCV (n=100)a N (%) |
|---|---|---|
| Headache | 3 (30) | 20 (20) |
| Fatigue | 7 (70) | 19 (19) |
| Nausea | 4 (40) | 12 (12) |
| Diarrhea | 2 (20) | 9 (9) |
| Insomnia | 3 (30) | 6 (6) |
| Abdominal pain | 3 (30) | 5 (5) |
| Arthralgia | 5 (50) | 5 (5) |
| Hematological adverse events | ||
| Hb | ||
| <90 (gL−1) | 0 (0) | 0 (0) |
| Lymphocytes | ||
| <0.5 (×109 L−1) | 1 (10) | 1 (1) |
| Neutrophil <0.75 (×109 L−1) | 6 (60) | 0 (0) |
| Platelet count <50 (×109 L−1) | 0 (0) | 1 (1) |
Note:
a
Derived from ALLY-3 trial (Nelson et al2)
Abbreviations: DCV, daclatasvir; GT3, genotype 3; Hb, hemoglobin; IFN, interferon; SOF, sofosbuvir.